Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University.  The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.

Genmab

Vivo Capital

Rock Springs Capital

Samsara BioCapital

Sofinnova Investments

Surveyor Capital

Novo Holdings

Pfizer Venture Investments

Pivotal bioVenture Partners

RA Capital Management

Bolt Biotherapeutics, Inc. 

#BoltBio management will be in New York for the Guggenheim Partners Healthcare Talks Biotech Conference. We look forward to connecting in person!

Today is #WorldCancerDay, and members of #TeamBolt are running in support of The DONNA Foundation and its Fight to FINISH #BreastCancer. Learn more about the DONNA Foundation here: https://bit.ly/4b5oMaJ

We’re just 1 week away from DONNA Marathon Weekend! #BoltBio is hosting this year’s Curb Crew, and encourages spectators to ring their cowbells loudly to support the runners. Learn more about The DONNA Foundation and their work to FINISH #breastcancer: https://bit.ly/48PVsUk 

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue		215K -	231K 7.44%	1.26M 445.45%	5.73M 354.68%	7.88M 37.48%
cost of revenue		26.00M -	40.36M 55.21%	3.67M 90.90%	4.89M 33.20%	1.88M 61.48%
gross profit		-25.79M -	-40.13M 55.61%	-2.41M 93.99%	838K 134.74%	5.99M 615.04%
selling and marketing expenses
general and administrative expenses	2.21M -	5.18M 134.59%	9.06M 74.76%	18.39M 103.10%	22.93M 24.65%	22.53M 1.73%
selling general and administrative expenses	2.21M -	5.18M 134.59%	9.06M 74.76%	18.39M 103.10%	22.93M 24.65%	22.53M 1.73%
research and development expenses	9.42M -	26.00M 176.03%	40.36M 55.21%	75.66M 87.46%	73.12M 3.35%	59.66M 18.41%
other expenses	-153K -	-42K 72.55%	-11.74M 27,864.29%	-6.08M 48.20%
cost and expenses	11.63M -	31.18M 168.16%	49.41M 58.46%	94.05M 90.33%	96.05M 2.13%	84.07M 12.47%
operating expenses	11.63M -	31.18M 168.16%	49.41M 58.46%	94.05M 90.33%	96.05M 2.13%	82.19M 14.43%
interest expense					-2.22M -
ebitda	-11.17M -	-30.59M 173.78%	-36.83M 20.38%	-85.51M 132.20%	-88.66M 3.68%	-74.31M 16.18%
operating income	-11.63M -	-30.97M 166.31%	-49.18M 58.81%	-92.79M 88.66%	-90.32M 2.66%	-76.20M 15.64%
depreciation and amortization	302K -	377K 24.83%	12.36M 3,177.45%	7.28M 41.11%	1.67M 77.11%	1.88M 13.09%
total other income expenses net	-153K -	482K 415.03%	-11.55M 2,495.44%	-5.80M 49.74%	2.22M 138.31%	7.00M 214.84%
income before tax	-11.59M -	-30.49M 163.07%	-60.73M 99.19%	-98.59M 62.35%	-88.10M 10.64%	-69.20M 21.45%
income tax expense	40K -	-482K 1,305%	11.55M 2,495.44%	5.80M 49.74%	-2.22M 138.31%
net income	-11.59M -	-30.00M 158.91%	-72.27M 140.87%	-104.39M 44.44%	-85.88M 17.74%	-69.20M 19.42%
weighted average shs out	9.42M -	35.10M 272.62%	36.25M 3.28%	37.40M 3.18%	37.36M 0.11%	37.81M 1.21%
weighted average shs out dil	9.42M -	35.10M 272.62%	36.25M 3.28%	37.40M 3.18%	37.36M 0.11%	37.81M 1.21%
eps	-1.23 -	-0.85 30.89%	-1.99 134.12%	-2.79 40.20%	-2.30 17.56%	-1.83 20.43%
epsdiluted	-1.23 -	-0.85 30.89%	-1.99 134.12%	-2.79 40.20%	-2.30 17.56%	-1.83 20.43%

NASDAQ:BOLT

Bolt Biotherapeutics

Last Close

0.74

26/07 20:00

Market Cap

27.47M

Beta: 0.99

Volume Today

138.00K

Avg: 250.78K

PE Ratio

−0.60

PFCF: −0.56

Preview